Guardant Health Reaches New 52-Week High of $127.70, Up 324%

Guardant Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 127.70 on May 27, 2026. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 324.18%, significantly outpacing the S&P 500's growth of 27.0% during the same period. As a midcap player in the Pharmaceuticals & Biotechnology industry, Guardant Health has demonstrated strong financial metrics, including an impressive return on equity of 427.38%. Despite being a loss-making entity, the company has managed to maintain a market capitalization of USD 11,435 million. The stock's price-to-book ratio stands at -115.15, indicating a unique valuation perspective within its sector. The stock's previous 52-week low was recorded at USD 37.73, highlighting the substantial upward movement in its price. This notable performance reflects the company's position in the market and its potential impact within the biotechnology landscape.